<DOC>
	<DOCNO>NCT00663000</DOCNO>
	<brief_summary>Observational , Cross-sectional , longitudinal , multi-center , diagnostic study Cross-sectional part study : To evaluate influence acromegaly glucose tolerance Longitudinal part study : To evaluate change impair glucose tolerance standard treatment acromegaly . Adult patient establish acromegaly Cross-sectional part study : 150 patient Longitudinal part study : 58 patient</brief_summary>
	<brief_title>Glucose Tolerance Acromegaly : The Influence GH-excess Glucose Metabolism Insulin Resistance</brief_title>
	<detailed_description>TRIAL DESIGN Observational , cross-sectional ( patient normal glucose tolerance ) . longitudinal ( patient impair glucose tolerance ) , multi-center , diagnostic study . After check inclusion exclusion criterion cross-sectional part study patient include anamnesis accord Flow Chart Visit -1 ( Screening Visit ) . After check glucose tolerance insulin resistance HOMA-IR , patient classify group normal glucose tolerance define : - fast plasma glucose &lt; 110 mg/dl and/or 2-hour plasma glucose OGTT &lt; 140 mg/dl group impair glucose tolerance define : - fast plasma glucose ≥ 110 mg/dl ( IFG ) and/or 2-hour plasma glucose OGTT ≥ 140 mg/dl ( IGT ) . For HOMA-IR cut 1.5 . For patient normal glucose tolerance study end Screening Visit ( V -1 ) . After patient recruitment cross-sectional part complete interim analysis plan verify criterion longitudinal study part achieve . The longitudinal part start later one year last patient examine cross-sectional part . For patient impaired glucose tolerance inclusion exclusion criterion longitudinal part study check ( Baseline , Visit 0 ) . If patient might include longitudinal part study 12 month observation 4 visit follow . Primary Objective Endpoint Cross-sectional part study : To evaluate correlation IGF-I glucose tolerance acromegalic patient . The inclusion perform 2 stratification group . Following two group define : 1 . 1/3 patient control IGF-I ( control mean IGF-I age sex-related normal reference range . 2 . 2/3 patient uncontrolled IGF-I ( uncontrolled mean IGF-I age sex relate normal reference range . Longitudinal part study : To evaluate change impair glucose tolerance different standard treatment option acromegaly . For analysis different treatment option patient stratify 5 treatment group . Decision make accord next plan therapeutic intervention Screening Visit ( V -1 ) : 1 . Surgery 2 . Treatment somatostatin analoga ( without combination dopamine agonist ) 3 . Treatment growth hormone receptor antagonist 4 . Treatment somatostatin analoga combination growth hormone receptor antagonist 5 . Others ( e.g . radiation , dopamine agonist monotherapy , intervention )</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>1 . Acromegaly adult subject ( ≥ 18 year ) either control uncontrolled ( Diagnosis base OGTT Acromegaly define lack suppression GH nadir &lt; 0.5 ng/dL , oral administration 75 g glucose , OGTT IGFI level least 10 % normal value ± 2 SD ) . 2 . Written inform consent 1 . Liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis , persistent ALT , AST , alkaline phosphatase 3 x &gt; upper limit normal , total bilirubin 2 x &gt; upper limit normal . 2 . Renal failure ( GFR ≤ 30 ml/min ) 3 . Abnormal clinical laboratory value consider investigator clinically significant could affect interpretation study result . 4 . History malignancy organ system , treat untreated , within past 3 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . 5 . Suspected known drug alcohol abuse . 6 . Any condition opinion investigator make patient unsuitable inclusion . 7 . Participation clinical trial investigational new drug . 8 . Patients longterm , continuous ( 2 weeks/year ) systemic therapy glucocorticosteroids exception substitution pituitary lack ACTH/cortisol ( e.g . patient panhypopituitarism ) . 9 . Instable heart insufficiency example cardiomyopathy , congestive heart failure ( NYHA class III IV ) , unstable angina , sustain ventricular tachycardia , ventricular fibrillation ) . 10 . Type I diabetes accord guideline European Diabetes Society obvious manifestation form diabetes ( e.g . steroid diabetes ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>acromegaly</keyword>
	<keyword>diabetes</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>impaired glucose tolerance</keyword>
</DOC>